FATE THERAPEUTICS INC
Company Stats
- Market Cap
- $284.0M
- as of Sep 30, 2026
- Shares Outstanding
- 119.8M
- Free Float
- 81.6%
Income Statement
- Revenue
- $6.6M
- Operating Income
- -$147.7M
- Net Income
- -$136.3M
- EBITDA
- -$134.8M
- Revenue Growth, 3Y
- -59.0%
- FCF Margin, 3Y Avg
- -936.8%
- FCF Margin, Worst Year
- -1685.8%
Cash Flow
- Free Cash Flow
- -$112.0M
- FCF Yield
- -39.5%
- Owner FCF Yield
- -48.2%
Balance Sheet
- Cash & Equivalents
- $46.6M
Returns & Capital
- SBC, 3Y Avg
- $36.6M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $6.6M | -$112.0M | -1685.8% |
| FY2024 | $13.6M | -$123.6M | -906.8% |
| FY2023 | $63.5M | -$138.4M | -217.9% |
| FY2022 | $96.3M | -$283.8M | -294.7% |
| FY2021 | $55.8M | -$213.6M | -382.4% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 30, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges